Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
NCT06115629 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 952
Last updated 2023-11-03
Summary
Cancer of the food pipe (oesophagus) and stomach are increasingly common. Currently, most patients with cancer of the oesophagus and stomach are treated with surgery with or without additional chemotherapy or radiotherapy. In recent years there have been improvements in survival from these two cancers, due to better therapies, less invasive surgery and earlier detection. Despite these improvements, in around half of patients treated with surgery, the cancer will return, usually within the first three years.
At present there is very little evidence as to how patients who have been treated for cancer of the oesophagus or stomach should be followed up after surgery and whether different methods of follow-up could improve survival. Currently, national and international guidelines do not provide consistency in their recommendations for follow-up after surgery.
The SARONG-II study will investigate if regular radiological scans can lead to earlier detection of a cancer returning, at a stage when it may be more readily treatable. This means that participants who agree to take part will be allocated by chance to either more intensive imaging surveillance (including regular radiological scans and a camera test (endoscopy)) or clinical follow-up.
The study aims to recruit at least 952 participants in Europe over a 32-month period. Patients undergoing surgery for oesophageal or stomach cancer will be invited to participate in the study at around 4 to 8 weeks after their surgery.
(i) The imaging surveillance group will receive a review in clinic or by telephone with a member of the surgical team, and a radiological scan at 6, 12, 18, 24, 30 and 36 months after randomisation. They will also receive endoscopy at 12 months after randomisation (ii) The clinical surveillance group will receive a review in clinic or by telephone at 6, 12, 18, 24, 30 and 36 months. After this they will be either discharged to their local doctor or receive a review in clinic with a member of the surgical team every year according to local practice
The main aim of this study will be to determine whether earlier detection of cancer through more intensive follow-up results in improved survival and better quality of life for patients with oesophagus or stomach cancer. The investigators anticipate the results of the study may have significant practice-changing impact for patients undergoing follow-up after surgery for oesophagus and stomach cancer.
Conditions
- Esophageal Cancer
- Gastric Cancer
Interventions
- OTHER
-
Surveillance protocol
Imaging surveillance will entail a computed tomography scan of the chest, abdomen and pelvis, as well as clinical review, every 6 months for 36 months post surgery along with an endoscopy at 12 months post surgery.
Sponsors & Collaborators
-
Trinity St. James's Cancer Institute
collaborator UNKNOWN -
University of Oxford
collaborator OTHER - collaborator OTHER
-
University of Dublin, Trinity College
lead OTHER
Principal Investigators
-
Jessie A Elliott, PhD FRCS · Trinity St. James's Cancer Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-30
- Primary Completion
- 2026-11-30
- Completion
- 2029-11-30
Countries
- Germany
- Ireland
- Italy
- Norway
- Sweden
Study Locations
More Related Trials
-
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
NCT00073502 ·Status: COMPLETED ·Phase: PHASE2
-
Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer
NCT03042169 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT04062058 ·Status: UNKNOWN ·Phase: PHASE2
-
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
NCT00525785 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection
NCT02572050 ·Status: UNKNOWN ·Phase: PHASE2
-
Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
NCT04923932 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer
NCT00260884 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
NCT04931420 ·Status: WITHDRAWN ·Phase: PHASE2
-
Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
NCT05728606 ·Status: UNKNOWN ·Phase: NA
-
Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer
NCT00587145 ·Status: UNKNOWN ·Phase: PHASE2
-
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
NCT05161572 ·Status: TERMINATED ·Phase: PHASE2
-
the Optimal Surveillance Frequency for Stage II/III Gastric Cancer
NCT05465993 ·Status: COMPLETED
-
Upfront Surgery Versus NeoAdjuvant Chemotherapy Followed by Surgery for Resectable Advanced Gastric Cancer: SNAC Study
NCT06472063 ·Status: RECRUITING
-
A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer
NCT00149279 ·Status: COMPLETED ·Phase: PHASE3
-
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
NCT06102785 ·Status: RECRUITING
-
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02205047 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427 ·Status: COMPLETED
-
T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
NCT02250209 ·Status: UNKNOWN ·Phase: PHASE2
-
Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer
NCT02725424 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy
NCT02404753 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07069712 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction
NCT05918419 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
NCT05395780 ·Status: UNKNOWN ·Phase: PHASE2
-
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
NCT04166721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2